Aileron Therapeutics, Inc. ("Aileron") (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of ...
A research group from Ningbo Institute of Materials Technology and Engineering (NIMTE) of the Chinese Academy of Sciences ...
A University of Colorado professor won the 2024 Alton Ochsner Award for his work on disease risk factors for idiopathic ...
Among patients with PPF, those treated with 60 mg of admilparant showed significant decreases in periostin, ferritin, and ...
A new statistical technique developed by a researcher at the Texas A&M University School of Public Health and colleagues ...
The positive phase 3 results showed improved lung function with nerandomilast vs placebo at 52 weeks in idiopathic pulmonary ...
The emerging therapies for the treatment of idiopathic pulmonary fibrosis include a great deal of emerging drugs Tyvaso (treprostinil), BI 1015550, and others. The emerging therapies in the ...
The German big pharma will submit a new drug application to the US FDA after success at phase 3 for nerandomilast.
After his brother's diagnosis, columnist Sam Kirton has new questions about the nature of familial idiopathic pulmonary fibrosis.
BackgroundIdiopathic pulmonary fibrosis (IPF) is a chronic progressive interstitial lung disease characterized by unexplained ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback